Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure

Kei Asayama, Takayoshi Ohkubo, Hirohito Metoki, Taku Obara, Ryusuke Inoue, Masahiro Kikuya, Lutgarde Thijs, Jan A. Staessen, Yutaka Imai*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

132 Citations (Web of Science)


Hypertension guidelines recommend blood pressure self-measurement at home (HBP), but no previous trial has assessed cardiovascular outcomes in hypertensive patients treated according to HBP. The multicenter Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure (HOMED-BP; 2001-2010) trial involved 3518 patients (50% women; mean age 59.6 years) with an untreated systolic/diastolic HBP of 135-179/85-119 mm Hg. In a 2 x 3 design, patients were randomized to usual control (125-134/80-84 mm Hg (UC)) vs. tight control (= 0.13) in the three drug groups. In all patients combined, the risk of the primary end point independently increased by 41% (6-89%; P = 0.019) and 47% (15-87%; P = 0.0020) for a 1-s.d. increase in baseline (12.5 mm Hg) and follow-up (13.2 mm Hg) systolic HBP. The 5-year risk was minimal (
Original languageEnglish
Pages (from-to)1102-1110
JournalHypertension Research
Issue number11
Publication statusPublished - Nov 2012


  • antihypertensive drug treatment
  • blood pressure control
  • home blood pressure
  • randomized clinical trial

Cite this